TandemLife is now a part of LivaNova, Learn More Here.
COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.
Pittsburgh-based medical device company CardiacAssist Inc. has changed its name to TandemLife to better reflect its future, and it has plans to nearly double the size of the company in 18 months. Privately held CardiacAssist began life 1996 and in 2001 rolled out its first product, TandemHeart, which provides people who need it with cardiac support. But
TandemLung is the newest addition to an expanding portfolio of medical devices offered by the manufacturer of the world’s first percutaneous circulatory support platform. PITTSBURGH, Penn., March 15, 2016 (PR Newswire) — CardiacAssist, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its new TandemLung® oxygenator, a